Patriot Financial Group Insurance Agency’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-1,788
Closed -$206K – 522
2024
Q3
$206K Hold
1,788
– – 0.03% 462
2024
Q2
$246K Sell
1,788
-70
-4% -$9.6K 0.04% 412
2024
Q1
$256K Buy
1,858
+20
+1% +$2.73K 0.04% 403
2023
Q4
$242K Buy
1,838
+3
+0.2% +$345 0.05% 383
2023
Q3
$206K Buy
+1,835
New +$193K 0.04% 417
2023
Q1
– Sell
-2,094
Closed -$250K – 480
2022
Q4
$250K Buy
+2,094
New +$245K 0.03% 354
2022
Q3
– Sell
-78
Closed -$8K – 1382
2022
Q2
$8K Sell
78
-13
-14% -$1.2K ﹤0.01% 1338
2022
Q1
$9K Buy
91
+52
+133% +$4.41K ﹤0.01% 1404
2021
Q4
$3K Sell
39
-50
-56% -$4.6K ﹤0.01% 1868
2021
Q3
$9K Buy
89
+23
+35% +$2.17K ﹤0.01% 1517
2021
Q2
$6K Sell
66
-16
-20% -$1.53K ﹤0.01% 1595
2021
Q1
$8K Sell
82
-22
-21% -$2.31K ﹤0.01% 1430
2020
Q4
$10K Sell
104
-6
-5% -$580 ﹤0.01% 1228
2020
Q3
$11K Buy
110
+5
+5% +$578 ﹤0.01% 1007
2020
Q2
$13K Buy
105
+20
+24% +$2.21K 0.01% 886
2020
Q1
$7K Buy
+85
New +$8.32K ﹤0.01% 980

Other funds holding NBIX

Patriot Financial Group Insurance Agency's NBIX Position: Q4 2024 in Review

Patriot Financial Group Insurance Agency sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 1,788 shares — an estimated $206K sold.

Patriot Financial Group Insurance Agency first reported a position in NBIX in Q1 2020 and held it in 16 quarters. The position peaked at $256K in Q1 2024. 601 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Patriot Financial Group Insurance Agency reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Patriot Financial Group Insurance Agency sold 1,788 Neurocrine Biosciences shares in Q4 2024, an estimated $206K.
  • Patriot Financial Group Insurance Agency first reported a position in Neurocrine Biosciences in Q1 2020 and held it in 16 quarters.
  • Patriot Financial Group Insurance Agency's Neurocrine Biosciences position peaked at $256K in Q1 2024.
  • 601 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Patriot Financial Group Insurance Agency's 13F filing for Q4 2024, filed 22 Jan 2025.